Piper Sandler Reiterates Overweight Rating on Globus Medical (GMED)
Tweet Send to a Friend
Piper Sandler analyst Matt O'Brien reiterated an Overweight rating and $115.00 price target on Globus Medical (NYSE: GMED).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


